People with type 2 diabetes usually have some resistance to insulin
We found that about 4 in 10 patients stopped their GLP-1 medication within the first year, and nearly 6 in 10 had stopped by the end of two years, based on insurance records from more than 60,000 Americans with type 2 diabetes, said study investigator Sainikhil Sontha
This may be due to the targeting effect of the failing myocardium-targeting peptide CTP in the nanoparticles, as achieving greater myocardial accumulation reduces the therapeutic dosage and attenuates pulmonary burden during nebulization
Frequently Asked Questions Which injection sites does the FDA labeling actually list
In very rare cases, allergic reactions may occur
Research Background In preclinical research settings, 5 Amino-1-MQ has been examined across a range of laboratory models, often in the context of: Cellular metabolism and energy-pathway research Enzyme-inhibition interaction studies Tissue and cell-line research models Published research summaries and references can be accessed via public scientific databases such as PubMed